The results run counter to ABYSS but align with other data showing beta-blockers shouldn’t continue indefinitely after MI.

The results, which are mostly relevant to an older population, address a common dilemma for aortic stenosis patients with CAD ...

The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?

Unique in its focus on adolescents, the trial shows the cardiac myosin inhibitor safely reduces LVOT in the pediatric ...

The first RCT to compare valve-in-valve vs redo surgery reassures, especially for regions where rheumatic valve disease is prevalent.

Mamas Mamas speaks with John Davies and J. Dawn Abbott about outcomes when treating patients with chronic total occlusions with PCI.

While the noninvasive methods used different technologies to calculate flow, both were noninferior to the gold standard.

Investigators suggest LDL targets typically reserved for secondary prevention are best in high-risk patients with diabetes.

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

The trial enrolled just half of its planned patients, leaving spironolactone’s role in HFpEF and HFmrEF still up in the air.

The results challenge the rapid growth of Impella support during high-risk PCI. Investigators say a reckoning is needed.

The program didn’t have a big impact on BP, but there were lessons for future attempts to address these health disparities.